Prellis: With $35M Bioprinting Investment Prellis Biologics Takes on New CEO
Organ bioprinting startup Prellis Biologics raised $35 million in a Series C round and plans to use the fresh capital to expand its proprietary, first-in-class human immune system-based drug discovery...The post With $35M Bioprinting Investment Prellis Biologics Takes on New CEO appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.
Read full article »
Prellis is a California-based biotechnology firm that develops and supplies 3D printed lymph nodes drug discovery and development systems for the healthcare industry.
Read more